Expanding Access to IWILFIN™ Outside the United States

Named Patient Program

US WorldMeds (“USWM”) and Tanner Pharma Group (“Tanner”) have jointly launched an innovative Named Patient Program (NPP) for IWILFIN (eflornithine) on a global scale. This collaboration will enable patient access to US WorldMeds’ IWILFIN, an FDA-approved medication, in regions where the drug is not commercially available.

Named Patient Programs are a mechanism through which physicians from other countries can legally and ethically prescribe FDA-approved drugs for patients in need prior to their local regulatory approval and commercial availability. However, it is important to acknowledge that medications not granted regulatory approval by local government bodies have not undergone their own comprehensive assessment of the potential risks and benefits. Healthcare providers and patients alike should evaluate all conceivable benefits and risks before pursuing access to an unapproved medicine within their jurisdiction.

Eligibility Criteria

Patients seeking access to IWILFIN are advised to consult directly with their healthcare provider.

To be eligible for the Named Patient Program, patients must have a medical condition that qualifies for treatment with IWILFIN. While there are no additional formal eligibility criteria for the USWM-Tanner program, there may be country specific restrictions for access. Healthcare providers should consult with Tanner Pharma Group to determine if their patient is eligible for accessing IWILFIN on a named patient basis.